Do you want to read an article? Please log in or register.
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Diabetes - GeneralType 1 DiabetesType 2 Diabetes
Related content
Type 2 DiabetesDiabetic Complications
SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
Diabetes Obes Metab.
Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K, Sun X
doi: 10.1111/dom.14075.
Type 1 DiabetesDiabetic Complications
Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis
Diabetes Care.
Hampp C, Swain RS, Horgan C, Dee E, Qiang Y, Dutcher SK, Petrone A, Chen Tilney R, Maro JC, Panozzo CA
doi: 10.2337/dc19-1481.
COMMENTED
Type 2 Diabetes
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
BMJ.
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B
doi: 10.1136/bmj.k4365.
COMMENTED
Type 1 Diabetes
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
Diabetes Care.
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M
doi: 10.2337/dc18-
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol.
Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z
doi: 10.1016/S2213-8587
Type 1 DiabetesDiabetic Complications
SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol
Diabetes Obes Metab.
Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC,
Zinman B
doi: 10.1111/dom.13811.
COMMENTED
Type 2 Diabetes
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Diabetes Obes Metab.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V
doi: 10.1111/dom.
RECOMMENDED
Type 2 Diabetes
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Lancet Diabetes Endocrinol.
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ
doi: 10.1016/